Pharmaceuticals

Gifthealth won a top digital health award, but its real victory is in redefining the prescription journey with faster delivery and better patient outcomes.

Clinuvel's SCENESSE® advances to a pivotal Phase III trial with a novel EMA-backed design, focusing on patient experience and visible results.

Millions are using GLP-1 drugs for weight loss, but an unexpected side effect is emerging: a prominent 'buffalo hump' that surgery is now targeting.

A new collaboration aims to slash neurologist wait times from months to days, as pharma giant Lilly expands its digital health ecosystem for chronic care.

As GLP-1 costs cripple employer health plans, Noom Health's new program bypasses industry middlemen, projecting massive savings and better patient outcomes.

With its Nasdaq debut, Lakewood-Amedex aims to accelerate its novel antimicrobial, Nu-3, a new weapon against antibiotic-resistant diabetic foot ulcers.

With its CMO and CSO now both recipients of the AHA's top honor, Cardiovascular Clinical Sciences signals a rare concentration of elite expertise.

A new non-viral gene therapy targeting iron buildup in the eye has completed its Phase I trial, offering a potential new path for millions with dry AMD.

ENA Respiratory appoints GSK veteran Melissa Faris to its board, a strategic move signaling an accelerated push for its innovative virus-agnostic nasal spray.

A novel RNA vaccine targeting hidden cancer antigens gets UK approval for a clinical trial, offering new hope for patients with hard-to-treat ovarian cancer.

Canadian giant Apotex acquires Cumberland's U.S. branded drugs for $100M, a move that expands its hospital presence and pivots Cumberland to a biotech.

Facing a crisis in patient access, Inizio unveils a next-gen hub using integrated analytics and pharmacy services to streamline the path to therapy.

A new T-cell therapy, RPTR-1-201, enters clinical trials, offering hope for hard-to-treat solid tumors by targeting a shared, multi-cancer marker.

TGA approves Minjuvi, a dual-targeted immunotherapy for relapsed follicular lymphoma, offering a breakthrough option beyond traditional chemotherapy.

After nine years of success, a renewed pact between Novonesis and Biocodex aims to dominate the booming global probiotics market. Here's what it means.

The life sciences advisory firm adds a heavy-hitter with $150B+ in deal experience, signaling ambitious growth and a new focus on the Southeast.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

As its leaders vie for a top entrepreneurial award, a look at how GenScript quietly became an indispensable engine for global scientific breakthroughs.

A new peer-reviewed study shows MECART cleanrooms cut emissions by 33%, challenging industry standards with verifiable data and a circular design.

For the 5th straight year, WA's life sciences outpace job growth. See how AI leadership and strategic investment fuel its $43.4B economic impact.